Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/33915
Title: Ondansetron is not superior to moderate dose metoclopramide in the prevention of post-operative nausea and vomiting after minor gynaecological surgery.
Authors: Monagle J.;Hewitt M.;Goodchild C.;Barnes R.
Institution: (Monagle, Barnes, Goodchild, Hewitt) Department of Anaesthesia, Monash Medical Center, Monash University, Clayton, Vic., Australia (Monagle) Department of Anaesthesia, Monash Medical Centre, Block E, 246 Clayton Road, Clayton, Vic. 3168, Australia
Issue Date: 19-Oct-2012
Copyright year: 1997
Publisher: Lippincott Williams and Wilkins (250 Waterloo Road, London SE1 8RD, United Kingdom)
Place of publication: United Kingdom
Publication information: European Journal of Anaesthesiology. 14 (6) (pp 604-609), 1997. Date of Publication: November 1997.
Abstract: Peri-operative nausea and vomiting (PONV), remain a considerable problem. Ondansetron is being promoted currently as the drug of choice for the prevention and treatment of PONV. Experiments to investigate efficacy of ondansetron in PONV have been made with placebo or single doses of other drugs, e.g. metoclopramide, and often with different anaesthetic regimes with different emetic potential. This study investigated the relative benefits, in the prevention of PONV, of ondansetron compared with metoclopramide used at a dose higher than used in previous studies. Ninety-six patients undergoing minor gynaecological surgery were randomized to receive either ondansetron 4 mg or metoclopramide 0.4 mg kg-1. The patients were then assessed in the recovery room, in the day ward prior to discharge and the following day for the occurrence of PONV. Emetic symptoms occurred in similar proportions of patients who received ondansetron and metoclopramide. Nausea scores were similar between the groups in the recovery ward and 24-h follow-ups but there were higher post-operative nausea scores in the ondansetron group in the day ward (P = 0.001). There were no significant side effects due to either drug. We conclude that moderate dose metoclopramide is an effective alternative to ondansetron in the control of PONV.
DOI: http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1097/00003643-199711000-00008
PubMed URL: 9466096 [http://www.ncbi.nlm.nih.gov/pubmed/?term=9466096]
ISSN: 0265-0215
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/33915
Type: Article
Type of Clinical Study or Trial: Randomised controlled trial
Appears in Collections:Articles

Show full item record

Page view(s)

16
checked on Sep 18, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.